October 11, 2024
Subjects continue to be enrolled in the Phase II part of TASKIN study, where they are receiving 1000mg of XBiotech’s True Human antibody Natrunix as part of their treatment for advanced colorectal cancer. The Phase II Dose has been established based on the results from the Phase I portion, which investigated the safety and preliminary efficacy of combining XB2001, with trifluridine/tipiracil (FTD/TPI) and bevacizumab in patients with metastatic colorectal cancer (mCRC). The Phase I part of the study provided valuable initial data on a novel combination therapy for mCRC, and the data is expected to be published in a leading peer reviewed journal soon.
The clinical portion of the study is funded by the French National Cancer Institute (INCA) and headed by Dr. Ghiringhelli and Dr. Come Lepage. Dr. Ghiringhelli, is a Professor in Medical Oncology and Director of the INSERM research team at the Georges-Francois Leclerc Cancer Centre, and Prof. Come Lepage, is a Professor in Gastroenterology and Digestive Oncology Department, University Hospital Dijon, Dijon, France.
Modern medicine should help patients feel better, not worse. At XBiotech, we believe in the Hippocratic principle of "do no harm." We believe this is inherent to the innovative True Human™ antibody medicines we are developing. True Human™ antibodies move beyond the idea that effective medicines must come with toxicity or harmful side effects.
By utilizing the body’s natural immune system, XBiotech develops therapies that help you heal and feel better.